benlysta belimumab
Selected indexed studies
- Belimumab (Benlysta®). (, 1994) [PMID:35951860]
- Belimumab (Benlysta®). (, 1994) [PMID:35951861]
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. (N Engl J Med, 2020) [PMID:32937045]
_Worker-drafted node — pending editorial review._
Connections
benlysta belimumab is a side effect of
Sources
- Belimumab (Benlysta®). (1994) pubmed
- Belimumab (Benlysta®). (1994) pubmed
- Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. (2020) pubmed
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. (2011) pubmed
- PMID:37903204 (2023) pubmed
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. (2011) pubmed
- Belimumab for systemic lupus erythematosus. (2021) pubmed
- Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study. (2022) pubmed
- Belimumab (Benlysta) for lupus nephritis. (2021) pubmed
- A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. (2022) pubmed